Progress in the Molecular Biology of Ewing Tumors
Open Access
- 1 January 1998
- Vol. 2 (1) , 3-17
- https://doi.org/10.1080/13577149878109
Abstract
Purpose/results/discussion. Rearrangement of the EWS gene with an ETS oncogene by chromosomal translocation is a hallmark of the Ewing family of tumors (EFT). Detectability, incidence, tumor specificity and variability of this aberration have been matters of intense investigation in recent years. A number of related alterations have also been found in other malignancies. The common consequence of these gene rearrangements is the generation of an aberrant transcription factor. In EFT, the ETS partner is responsible for target recognition. However, synergistic and possibly tissue-restricted transcription factors interacting with either the EWS or the ETS portion may influence target selection. Minimal domains of both fusion partners were defined that have proved necessary for the in vitro transformation of murine fibroblasts. These functional studies suggest a role for aberrant transcriptional regulation of transforming target genes by the chimeric transcription factors. Also, fusion of the two unrelated protein domains may affect overall protein conformation and consequently DNA binding specificity. Recent evidence suggests that EWS, when fused to a transcription factor, interacts with different partners than germ-line EWS. Variability in EWS–ETS gene fusions has recently been demonstrated to correlate with clinical outcome. This finding may reflect functional differences of the individual chimeric transcription factors. Alternatively, type and availability of specific recombinases at different time-points of stem cell development or in different stem cell lineages may determine fusion type. Studies on EFT cell lines using EWS–ETS antagonists do suggest a rate-limiting essential role for the gene rearrangement in the self-renewal capacity of EFT cells. The presence of additional aberrations varying in number and type that may account for immortalization and full transformation is postulated. Knowledge about such secondary alterations may provide valuable prognostic markers that could be used for treatment stratification.Keywords
This publication has 96 references indexed in Scilit:
- Molecular Cloning and Subcellular Localisation of the snRNP-associated Protein 69KD, a Structural Homologue of the Proto-oncoproteins TLS and EWS, with RNA and DNA-binding PropertiesJournal of Molecular Biology, 1996
- Mobilization of tumour cells during biopsy in an infant with Ewing sarcomaEuropean Journal of Pediatrics, 1996
- A Novel Chimera Gene betweenEWSandE1A-F, Encoding the Adenovirus E1A Enhancer-Binding Protein, in Extraosseous Ewing's SarcomaBiochemical and Biophysical Research Communications, 1996
- Modulation of Transcription Factor Ets-1 DNA Binding: DNA-Induced Unfolding of an α HelixScience, 1995
- Minimal metastatische - und minimal residuelle Erkrankung bei Patienten mit Ewing-TumorenKlinische Padiatrie, 1995
- Cyclins, Cyclin-Dependent Kinases and Cdk Inhibitors: Implications in Cell Cycle Control and CancerCritical Reviews™ in Eukaryotic Gene Expression, 1995
- Cloning of the entire FL11 gene, disrupted by the Ewing’s Sarcoma translocation breakpoint on 11q24, in a yeast artificial chromosomeCytogenetic and Genome Research, 1994
- Insulin-like growth factor-I-dependent growth and in vitro chemosensitivity of Ewing's sarcoma and peripheral primitive neuroectodermal tumour cell linesEuropean Journal Of Cancer, 1993
- Type I and type II insulin-like growth factor receptors and their function in human Ewing's sarcoma cellsZeitschrift für Krebsforschung und Klinische Onkologie, 1992
- Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor.Journal of Clinical Investigation, 1990